Pentosan Polysulphate Sodium

Interstitial cystitis
Adult: 100 mg tid.
Patients who are haemorrhaging. Serious renal or hepatic impairment. Not to be given via IM inj.
Warnings / Precautions
Patients with spleen disorders, hepatic or renal impairment. Monitor platelet counts during treatment. To discontinue treatment if thrombocytopenia occurs. Caution when used in patients with haemorrhagic blood disorders, thrombocytopenia, peptic ulcer disease, cerebrovascular disorders, bacterial endocarditis, severe hypertension or oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Safety not established in children <16 yr. Patients should be monitored every 3 mth; risks and benefits after 6 mth of treatment not known. Pregnancy; lactation.
Adverse Reactions
Local irritation, skin necrosis; alopecia and osteoporosis may occur upon prolonged treatment; hyperkalaemia and bleeding; nausea, diarrhoea, headache, fatigue, drowsiness, pelvic pain, rectal haemorrhage, dyspepsia, abdominal pain; LFT abnormalities.
Overdose Reactions
Symptoms: Anticoagulation, bleeding, thrombocytopenia, liver function abnormalities and gastric distress. Treatment: Gastric lavage and symptomatic and supportive therapy.
Drug Interactions
Increased risk of bleeding when used with oral anticoagulants or drugs that affect platelet function. Concurrent admin with glyceryl trinitrate via IV route may reduce the efficacy of pentosan.
See Below for More pentosan polysulfate sodium Drug Interactions
Mechanism of Actions
Pentosan polysulfate sodium is a heparinoid with anticoagulant and fibrinolytic properties; it may also have hypolipidaemic and anti-inflammatory effects. It is used in thromboembolic disorders, although its anticoagulant effect is less than that of heparin. It is also used in the management of interstitial cystitis and has been tried in a number of other conditions, including variant Creutzfeldt-Jakob disease.
Absorption: Approx 6%.
Metabolism: Hepatic and via spleen; some in renal parenchyma.
Excretion: Half-life elimination: 20-27 hr. Excretion via urine (6%, mainly as metabolites); faeces (58-84%, as unchanged drug).
Should be taken on an empty stomach. (Take at least 1 hr before or 2 hr after meals.)
Storage Conditions
Oral: Store at 15-30 °C.
ATC Classification
C05BA04 - pentosan polysulfate sodium ; Belongs to the class of heparins or heparinoids used topically in antivaricose therapy.
Oral: Store at 15-30 °C.
Available As
  • Pentosan Polysulphate Sodium 100 mg
  • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Pentosan Polysulphate Sodium

    Pentosan Polysulphate Sodium Containing Brands

    We are Developing Our database, More results coming soon.

    Pentosan Polysulphate Sodium is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Pentosan Polysulphate Sodium

    We are Developing Our database, More results coming soon.